Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05890352 2025-10-20

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

227 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06029309 2025-10-06

ZANU-TAFA

Phase 1/2 Recruiting

27 enrolled

Lymphoma, Mantle-Cell

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05626322 2025-09-05

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1/2 Terminated

6 enrolled 17 charts

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07126236 2025-08-17

REPIFIR

80 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05583071 2025-08-13

MTR²

20 enrolled

Lymphoma, Non-Hodgkin

NCT06792825 2025-08-12

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

65 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT02763319 2025-07-17

B-MIND

Phase 2/3 Completed

453 enrolled 29 charts

Lymphoma, Large B-Cell, Diffuse

NCT05788289 2025-05-25

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Phase 2 Terminated

4 enrolled 8 charts

Lymphoma, Mantle-Cell

NCT04981795 2024-12-10

realMIND

Recruiting

100 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05910801 2024-11-18

V-MIND

100 enrolled

Lymphoma, Mantle-Cell

NCT04134936 2024-10-16

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Phase 1 Completed

66 enrolled 21 charts

Lymphoma, Large B-Cell, Diffuse

NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Phase 2 Terminated

3 enrolled 6 charts

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT01685008 2023-11-07

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Phase 2 Completed

92 enrolled 37 charts

81 enrolled 23 charts 3 FDA

Lymphoma, Non-Hodgkin

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

Other hematologic neoplasm

Lymphoma, Large B-Cell, Diffuse

NCT05205252 2023-08-15

ARIA

Phase 1/2 Withdrawn

Hematologic Neoplasms

NCT05883709 2023-06-01

A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

Unknown

15 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02639910 2021-12-20

COSMOS

Phase 2 Completed

24 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04882163 2021-10-05

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Phase 1/2 Withdrawn

Lymphoma, B-Cell

NCT04300803 2020-08-28

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Approved for marketing

Lymphoma, Large B-Cell, Diffuse

NCT01685021 2018-02-22

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Phase 2 Terminated

22 enrolled 12 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01161511 2014-04-21

Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia

Phase 1 Completed

27 enrolled